Flora Growth (NASDAQ:FLGC – Get Free Report) and NovoCure (NASDAQ:NVCR – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability and earnings.
Earnings and Valuation
This table compares Flora Growth and NovoCure”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Flora Growth | $57.61 million | 0.05 | -$15.91 million | ($32.49) | -0.09 |
| NovoCure | $655.35 million | 2.39 | -$136.23 million | ($1.06) | -12.67 |
Flora Growth has higher earnings, but lower revenue than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Flora Growth, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Flora Growth has a beta of 1.9, indicating that its share price is 90% more volatile than the S&P 500. Comparatively, NovoCure has a beta of 0.99, indicating that its share price is 1% less volatile than the S&P 500.
Institutional and Insider Ownership
36.0% of Flora Growth shares are owned by institutional investors. Comparatively, 84.6% of NovoCure shares are owned by institutional investors. 2.3% of Flora Growth shares are owned by insiders. Comparatively, 6.6% of NovoCure shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Profitability
This table compares Flora Growth and NovoCure’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Flora Growth | -32.03% | -64.02% | -34.46% |
| NovoCure | -21.25% | -44.00% | -15.85% |
Analyst Recommendations
This is a summary of recent recommendations for Flora Growth and NovoCure, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Flora Growth | 1 | 0 | 0 | 0 | 1.00 |
| NovoCure | 1 | 4 | 2 | 0 | 2.14 |
NovoCure has a consensus price target of $20.80, indicating a potential upside of 54.88%. Given NovoCure’s stronger consensus rating and higher possible upside, analysts clearly believe NovoCure is more favorable than Flora Growth.
Summary
NovoCure beats Flora Growth on 11 of the 14 factors compared between the two stocks.
About Flora Growth
Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products. It also offers food and beverage, nutraceuticals, cannabis accessories and technology, personal care, and wellness; cannabidiol (CBD) derived products, such as gummies, topicals, tinctures, and vape products; cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herbs. In addition, the company manufactures and distributes pharmaceutical goods and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants. The company sells its products under the JustCBD, Vessel, and Phatebo brands. Flora Growth Corp. was incorporated in 2019 and is based in Fort Lauderdale, Florida.
About NovoCure
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Receive News & Ratings for Flora Growth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flora Growth and related companies with MarketBeat.com's FREE daily email newsletter.
